Your browser doesn't support javascript.
loading
Human Papillomavirus neutralizing and cross-reactive antibodies induced in HIV-positive subjects after vaccination with quadrivalent and bivalent HPV vaccines.
Faust, Helena; Toft, Lars; Sehr, Peter; Müller, Martin; Bonde, Jesper; Forslund, Ola; Østergaard, Lars; Tolstrup, Martin; Dillner, Joakim.
Afiliación
  • Faust H; Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden.
  • Toft L; Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.
  • Sehr P; European Molecular Biology Laboratory, Heidelberg, Germany.
  • Müller M; German Cancer Research Center, Heidelberg, Germany.
  • Bonde J; Molecular Pathology Laboratory, Department of Pathology, Copenhagen University Hospital, Hvidovre, Denmark.
  • Forslund O; Department of Laboratory Medicine, Lund University, Malmö, Sweden.
  • Østergaard L; Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.
  • Tolstrup M; Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.
  • Dillner J; Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden. Electronic address: joakim.dillner@ki.se.
Vaccine ; 34(13): 1559-1565, 2016 Mar 18.
Article en En | MEDLINE | ID: mdl-26896686
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Seropositividad para VIH / Reacciones Cruzadas / Vacunas contra Papillomavirus / Vacuna Tetravalente Recombinante contra el Virus del Papiloma Humano Tipos 6, 11 , 16, 18 / Anticuerpos Antivirales Tipo de estudio: Clinical_trials Límite: Female / Humans / Male / Middle aged Idioma: En Revista: Vaccine Año: 2016 Tipo del documento: Article País de afiliación: Suecia
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Seropositividad para VIH / Reacciones Cruzadas / Vacunas contra Papillomavirus / Vacuna Tetravalente Recombinante contra el Virus del Papiloma Humano Tipos 6, 11 , 16, 18 / Anticuerpos Antivirales Tipo de estudio: Clinical_trials Límite: Female / Humans / Male / Middle aged Idioma: En Revista: Vaccine Año: 2016 Tipo del documento: Article País de afiliación: Suecia